Dr. An Gang

• Director of the Lymphoma Diagnosis and Treatment Center
• Postdoctoral Fellow at the Dana-Farber Cancer Institute of Harvard University
• Specializes in the diagnosis and treatment of blood diseases such as multiple myeloma and lymphoma
• Young Director of the Chinese Anti-Cancer Association
• Secretary-General of the CSCO Multiple Myeloma Expert Committee
• Vice Chairman of the Second Youth Committee of Hematological Tumors under the Chinese Anti-Cancer Association
• Member of the Youth Committee of the 11th Committee of the Hematology Branch of the Chinese Medical Association
• Member of the Hematological Disease Translation Committee of the Chinese Anti-Cancer Association
• Member of the Tumor Nephrology Professional Committee of the Chinese Anti-Cancer Association
• Member and Secretary of the China Multiple Myeloma Research Alliance
• Principal Investigator of three National Natural Science Foundation projects
• Recipient of the 2020 China Oncology Young Scientist Award
• Recognized as a first-level talent under Tianjin’s “131” Innovative Talent Training Project
• Honored as a young medical newcomer in Tianjin’s Health and Family Planning Industry High-Level Talent Selection and Training Project

Postdoctoral fellow at Dana-Farber Cancer Institute, Harvard University; presided over three National Natural Science Foundation projects; won the 2020 China Oncology Young Scientist Award; first-level talent in Tianjin’s “131” Innovative Talent Training Project; young medical talent in Tianjin’s Health and Family Planning Industry High-level Talent Selection and Training Project.

Dr. An Gang specializes in the diagnosis and treatment of hematological diseases, particularly multiple myeloma and lymphoma. He is the Director of the Lymphoma Diagnosis and Treatment Center and a postdoctoral fellow at the Dana-Farber Cancer Institute of Harvard University. Additionally, he has leadership roles in various hematology-related committees in China and has received numerous awards for his contributions to oncology research.

Dr. An Gang provides specialized treatments for hematological diseases, particularly lymphoma and multiple myeloma. His expertise includes personalized treatment plans using targeted therapies, immunotherapies, chemotherapy, and stem cell transplantation. He is involved in advancing research on innovative therapies, contributing to better patient outcomes.

1. CAR T-Cell Therapy: Specializes in Chimeric Antigen Receptor (CAR) T-cell therapy, an innovative immunotherapy that harnesses the power of a patient’s immune cells to target and destroy cancer cells, particularly for relapsed or refractory leukemia and lymphoma.
2. Chemotherapy: Administers tailored chemotherapy regimens for acute and chronic leukemia, lymphoma, and multiple myeloma.
3. Targeted Therapy: Utilizes targeted drugs to treat specific genetic mutations in leukemia and other blood cancers, enhancing treatment efficacy with fewer side effects.
4. Immunotherapy: Offers advanced immunotherapies, including monoclonal antibodies and immune checkpoint inhibitors, to boost the body’s immune response against cancer.
5. Hematopoietic Stem Cell Transplantation (HSCT): Specializes in autologous and allogeneic stem cell transplantation to treat leukemia, lymphoma, and myelodysplastic syndromes (MDS).
6. Precision Medicine: Develops personalized treatment plans based on genetic and molecular diagnostics to improve patient outcomes.
7. Supportive Care: Provides comprehensive supportive care, including infection management, transfusions, and symptom control during and after treatment.
8. Clinical Trial Access: Facilitates patient participation in cutting-edge clinical trials, offering access to novel therapies and investigational drugs.

Dr. An Gang has conducted extensive research in the field of hematological malignancies, focusing on the diagnosis and treatment of multiple myeloma and lymphoma. His work includes clinical trials, targeted therapies, and immunotherapy research. He has contributed to numerous scientific publications, collaborating with leading researchers worldwide. Additionally, he has led several National Natural Science Foundation projects.